Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · IEX Real-Time Price · USD
33.72
-0.02 (-0.06%)
Mar 28, 2024, 2:10 PM EDT - Market open
Supernus Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 - 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|
Cash & Equivalents | 75.05 | 93.12 | 203.43 | 288.64 | 181.38 | 192.25 | 100.3 | 66.4 | 33.5 | 36.4 | Upgrade
|
Short-Term Investments | 179.82 | 368.21 | 136.25 | 133.89 | 165.69 | 163.77 | 39.74 | 23.72 | 28.69 | 37.94 | Upgrade
|
Cash & Cash Equivalents | 254.87 | 461.33 | 339.68 | 422.53 | 347.07 | 356.02 | 140.04 | 90.12 | 62.19 | 74.34 | Upgrade
|
Cash Growth | -44.75% | 35.81% | -19.61% | 21.74% | -2.51% | 154.23% | 55.39% | 44.91% | -16.34% | -9.56% | Upgrade
|
Receivables | 144.16 | 165.5 | 148.93 | 140.88 | 87.33 | 102.92 | 65.59 | 41.53 | 25.91 | 17.27 | Upgrade
|
Inventory | 77.41 | 91.54 | 85.96 | 48.33 | 26.63 | 25.66 | 16.3 | 16.8 | 12.59 | 13.44 | Upgrade
|
Other Current Assets | 16.68 | 15.78 | 27.02 | 18.68 | 11.61 | 8.89 | 6.52 | 2.96 | 5.26 | 3.68 | Upgrade
|
Total Current Assets | 493.11 | 734.15 | 601.59 | 630.42 | 472.64 | 493.49 | 228.45 | 151.4 | 105.95 | 108.73 | Upgrade
|
Property, Plant & Equipment | 13.53 | 15.17 | 16.96 | 37.82 | 17.07 | 4.1 | 5.12 | 4.34 | 3.87 | 2.45 | Upgrade
|
Long-Term Investments | 16.62 | 93.9 | 119.17 | 350.36 | 591.77 | 418.8 | 133.64 | 75.41 | 55.01 | 19.82 | Upgrade
|
Goodwill and Intangibles | 716.91 | 819.48 | 902.21 | 442.25 | 24.84 | 31.37 | 36.02 | 36.35 | 0.98 | 0.23 | Upgrade
|
Other Long-Term Assets | 37.51 | 39.81 | 49.23 | 43.25 | 53.96 | 30.06 | 21.23 | 42.06 | 22.82 | 5.57 | Upgrade
|
Total Long-Term Assets | 784.56 | 968.36 | 1,088 | 873.69 | 687.64 | 484.32 | 196.01 | 158.16 | 82.68 | 28.06 | Upgrade
|
Total Assets | 1,278 | 1,703 | 1,689 | 1,504 | 1,160 | 977.81 | 424.46 | 309.57 | 188.63 | 136.78 | Upgrade
|
Accounts Payable | 79.57 | 96.34 | 117.68 | 78.93 | 49.71 | 3.2 | 6.84 | 8.06 | 4.31 | 1.86 | Upgrade
|
Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1.44 | 1.71 | 1.57 | 1.42 | Upgrade
|
Current Debt | 0 | 401.97 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
Other Current Liabilities | 210.63 | 189.65 | 197.7 | 166.17 | 110.87 | 158.16 | 114.72 | 70.98 | 51.05 | 24.84 | Upgrade
|
Total Current Liabilities | 290.2 | 687.96 | 315.38 | 245.11 | 160.59 | 161.35 | 123 | 80.74 | 56.93 | 28.12 | Upgrade
|
Long-Term Debt | 33.2 | 36 | 420.55 | 390.33 | 375.61 | 329.46 | 0 | 4.17 | 7.09 | 26.22 | Upgrade
|
Other Long-Term Liabilities | 32.77 | 92.35 | 137.37 | 123.81 | 28.66 | 33.97 | 33.98 | 32.91 | 36.6 | 41.74 | Upgrade
|
Total Long-Term Liabilities | 65.96 | 128.35 | 557.92 | 514.14 | 404.27 | 363.44 | 33.98 | 37.07 | 43.69 | 67.96 | Upgrade
|
Total Liabilities | 356.16 | 816.3 | 873.3 | 759.24 | 564.85 | 524.79 | 156.98 | 117.81 | 100.62 | 96.09 | Upgrade
|
Total Debt | 33.2 | 437.97 | 420.55 | 390.33 | 375.61 | 329.46 | 0 | 4.17 | 7.09 | 26.22 | Upgrade
|
Debt Growth | -92.42% | 4.14% | 7.74% | 3.92% | 14.01% | - | - | -41.21% | -72.98% | -23.75% | Upgrade
|
Retained Earnings | 482.56 | 481.25 | 379.92 | 326.5 | 199.55 | 86.49 | -26.82 | -84.29 | -175.51 | -189.45 | Upgrade
|
Comprehensive Income | -0.59 | -3.21 | 1.54 | 8.98 | 7.42 | -3.16 | -0.75 | -0.13 | -0.49 | -0.15 | Upgrade
|
Shareholders' Equity | 921.52 | 886.2 | 815.85 | 744.86 | 595.43 | 453.02 | 267.48 | 191.76 | 88.01 | 40.7 | Upgrade
|
Net Cash / Debt | 221.68 | 23.37 | -80.87 | 32.2 | -28.54 | 26.56 | 140.04 | 85.96 | 55.11 | 48.11 | Upgrade
|
Net Cash / Debt Growth | 848.64% | - | - | - | - | -81.04% | 62.92% | 55.99% | 14.53% | 0.66% | Upgrade
|
Net Cash Per Share | 3.99 | 0.38 | -1.49 | 0.60 | -0.53 | 0.49 | 2.63 | 1.66 | 1.08 | 1.14 | Upgrade
|
Working Capital | 202.92 | 46.19 | 286.21 | 385.31 | 312.06 | 332.13 | 105.45 | 70.66 | 49.01 | 80.6 | Upgrade
|
Book Value Per Share | 16.90 | 16.51 | 15.37 | 14.16 | 11.36 | 8.71 | 5.27 | 3.88 | 1.85 | 0.96 | Upgrade
|